BioCryst Pharmaceuticals ( (BCRX) ) has released its Q4 earnings. Here is a breakdown of the information BioCryst Pharmaceuticals presented to its investors.
BioCryst Pharmaceuticals is a biotechnology company focused on developing oral small-molecule and protein therapeutics for rare diseases, including hereditary angioedema (HAE). The company has commercialized ORLADEYO, a once-daily oral treatment for HAE attacks.
In its latest earnings report, BioCryst Pharmaceuticals announced a significant increase in ORLADEYO net revenue, reaching $124.2 million in the fourth quarter of 2024, a 36.6% year-over-year increase. For the full year 2024, ORLADEYO generated $437.7 million in net revenue, marking a 34.3% increase from the previous year. The company has raised its 2025 revenue guidance for ORLADEYO to between $535 million and $550 million.
Key financial highlights include a GAAP operating loss of $2.5 million for the full year 2024, with a non-GAAP operating profit of $62.9 million, excluding stock-based compensation. The company also reported a decrease in research and development expenses, while selling, general, and administrative expenses increased due to expanded commercial activities. BioCryst is advancing its rare disease pipeline, with plans to expand ORLADEYO’s label to children with HAE and initiate clinical trials for BCX17725 and avoralstat.
Looking ahead, BioCryst Pharmaceuticals expects to achieve positive earnings per share and cash flow in the second half of 2025, with a continued focus on revenue growth and strategic pipeline development. The company aims to maintain its momentum by expanding its product offerings and market reach in the coming years.